1 domain / 2 areas / 1 specialization
Noetic Fund
Also known as: Noetic
Data updated
Noetic Fund is a Toronto-based venture firm investing in early-stage technologies focused on mental health and wellbeing. Its public materials describe a diversified strategy across novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables, and other evidence-backed solutions, with a global outlook and emphasis on early intervention and prevention.
The firm is explicitly tied to the psychedelic medicine ecosystem through its own fund announcements, reading list, and portfolio disclosures. Publicly named investments include CaaMTech, the Alexander Shulgin Research Institute, and Damona Pharmaceuticals, which positions Noetic as an active capital provider in psychedelic drug development and adjacent mental health innovation.
Investor Context
Social-Impact InvestorsInvestment Context
This stakeholder is listed as a Social-Impact Fund within Social-Impact Investors. Its public geography context is global. Public stage signals include Seed, Series A/B, and Multi-Stage. Public focus areas include Drug Development, Mental Health Access Equity, and Policy & Advocacy.
Public Portfolio Examples
- CaaMTechSeries A financing - $22m Series A - Sep 15, 2022
- Alexander Shulgin Research InstituteSeries A financing - $8m+ Series A - Dec 20, 2022
Noetic Fund presents itself as a venture investor in early-stage mental health and wellbeing technologies, with a strategy that combines psychedelic medicine, drug discovery, digital health, and other evidence-backed modalities. Its public portfolio and announcements show repeated participation in psychedelic and CNS-related financings, including CaaMTech, the Alexander Shulgin Research Institute, and Damona Pharmaceuticals. The firm’s materials frame the work as global in scope and oriented toward therapies and services that address root causes of illness and improve access to care.
Investor Type
Social-Impact Fund
Geographic Scope
Global
Psychedelic Focus
Explicit Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Dec 20, 2022
Series A financing - $8m+ Series A
ASRI raises over $8m in Series ADamona Pharmaceuticals
Sep 26, 2022
Seed financing (co-led) - $5.5m seed round
Damona raises $5.5m seed financingDec 9, 2021
Seed - $6.95M
Seed investment in a psychedelic drug discovery company focused on novel compounds and the Shulgin Vault.
Noetic Commits to Investing $6.95M into Seed Round for The Alexander Shulgin Research Institute for Psychedelic Drug Discovery and DevelopmentQuick Facts
- Founded
- 2020
- HQ
- 501-302 Bay Street, Toronto, Ontario M5H 0B6, Canada
- Website
- Visit